![](/img/cover-not-exists.png)
PCN5 COST-UTILITY ANALYSIS OF ANASTROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER (EBC): A UK NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE
R Brown, A Benedict, RE ManselVolume:
7
Year:
2004
Language:
english
DOI:
10.1016/s1098-3015(10)65739-7
File:
PDF, 64 KB
english, 2004